Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI:10.1038/s41571-024-00953-4

Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna

引用次数: 0

查看原文本刊更多论文

回复 "NALIRIFOX在转移性胰腺癌一线治疗中的应用：NAPOLI 3以外的证据

我们感谢 Wainberg 和 O'Reilly 对我们最近发表的《新闻与观点》（News & Views）一文的关注，该文批评了 NAPOLI 3 试验的设计和结果报告（Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX 治疗转移性胰腺腺癌：希望还是炒作？Nat.Rev. Clin.Oncol.21, 567-568 (2024))1.在他们的通信（Wainberg, Z. A. & O'Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat.Rev. Clin.https://doi.org/10.1038/s41571-024-00952-5 (2024))2，他们提出了几点我们希望解决的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.